Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTOR: Temsirolimus in Advanced Bladder Cancer
NCT01827943Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Jun 2009
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in bladder cancer, sponsored by Institut Bergonié. Primary endpoint: Non-progression Rate at 2 Months. Started Jun 2009; status: completed.
02
Drugs
temsirolimus
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT01827943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827943.